Haemonetics reported second‑quarter fiscal 2026 results that surpassed analyst expectations, with revenue of $327.32 million and adjusted earnings per share of $1.27, a $0.15 beat over the consensus estimate of $1.12.
Revenue fell 5.3% year‑over‑year to $327.32 million, driven by a 5.1% growth in the Hospital segment and a decline in the Plasma and Blood Center segment. Organic revenue, excluding the impact of the CSL Plasma transitional agreement, grew 9.4%, underscoring the strength of the company’s core product mix.
Gross margin expanded to 59.5% from 54.2% a year earlier, while adjusted operating margin rose to 26.7% from 24.7%, a 250‑basis‑point gain. The improvement reflects a shift toward higher‑margin core products such as Nexus, TEG, and vascular closure, combined with disciplined cost management that offset the revenue decline.
Management raised its full‑year fiscal 2026 adjusted EPS guidance to $4.80–$5.00 from the prior $4.70–$5.00, and lifted revenue guidance to a 1%–4% decline versus the previous 3%–6% decline outlook. Free‑cash‑flow guidance was also increased, signaling confidence in continued cash‑generating strength amid the company’s strategic transformation.
CEO Chris Simon said the quarter “demonstrates disciplined execution and increasingly profitable growth across our business—growing cash flow, earnings and operating income while absorbing the impact from last year’s portfolio transitions.” CFO James D'Arecca added that the company’s growth and profitability are anchored in the success of its three core products, reinforcing the focus on high‑margin offerings.
Investors responded favorably to the earnings beat, margin expansion, and raised guidance, reflecting confidence in Haemonetics’ ability to sustain profitability while navigating a revenue decline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.